OHE Publications

OHE releases a number of publications throughout the year, authored by OHE team members and/or outside experts. All are free for download as pdf files; hard copies of some publications are available upon request.

A description of the OHE publications categories.


 

Yasunaga, H., Yamana, H., Rodes Sanchez, M. and Towse, A.

Consulting Report
September 2019

In 2015, OHE Consulting published a report on data governance arrangements for real-world evidence (RWE) covering the specifics under which RWE was used in eight different countries: Australia, France, Germany, Italy, Sweden, the Netherlands, the UK and the US1. Two years later, Lilly commissioned a second report based on the South Korean setting, following the same method and structure as the original2.

Berdud, M., Wallin-Bernhardsson, N., Zamora, B., Lindgren, P., and Towse, A.

Research Paper
July 2019

The present work aims to assess the life-cycle value of innovative medicines based on the example of Second-Generation Antipsychotics (SGA). Assessing the entire life-cycle of SGA, the study explores how much additional value has been delivered through additional approved indications for SGAs, generic competition or new and clinically superior formulations launched. Using risperidone as representative of the SGA class and comparing it to haloperidol – its counterpart from the First-Generation Antipsychotics (FGA) – this research estimates the life-cycle cost-effectiveness of the SGA class against FGA class in incremental terms. It also estimates the absolute social value added, measured by the sum of the consumer and producer surpluses. Study results aim to quantify the nature of value added by pharmaceutical innovation over the long-run to support consideration as to how access decisions can be informed by these life cycle effects.

Cole, A., Towse, A. and Zamora, B.

Briefing
June 2019

Cada vez más, los avances científicos desarrollan nuevas medicinas que permiten mejoras en la supervivencia y calidad de vida para diversas indicaciones terapéuticas. La fijación de precios en función de la indicación se ha propuesto como un modo de relacionar el precio con el valor. En este breve documento de debate, explicamos los aspectos más importantes como los posibles beneficios IBP, posibles inconvenientes, y consideraciones para la implementación. Nos gustaría conocer su opinión. Fecha de cierre de la consulta: lunes, 30 de septiembre de 2019.

Cole, A., Towse, A. and Zamora, B.

Briefing
May 2019

Increasingly, scientific advances are delivering new medicines that deliver improved survival and quality of life across multiple treatment indications. Indication-Based Pricing (IBP) has been proposed as a way to better link price with value. In this short Discussion Paper, we outline the major issues including the potential benefits of IBP, potential draw-backs, and considerations for implementation. We then ask for your views.

To submit your thoughts, please access the survey which accompanies the Discussion Paper or use the following link: https://www.surveymonkey.co.uk/r/IBP_Consultation

Consultation closing date: Monday, 30 September 2019.

Cole, A., Towse, A., Segal, C.S., Henshall, C. and Pearson, S.D.

Research Paper
March 2019

OHE Research Paper 19/02: The combination of rising drug costs in the US and increasing financial stress for individual patients has triggered intense national concern. One target has come under particular scrutiny: rebates. This paper describes how alternatives to the current US rebate system offer potential risks or disadvantages as well as potential benefits. It outlines the evidence presented to date, and the key questions that still need to be answered.

Cole, A. and Towse, A.

Consulting Report
December 2018

The proliferation of health data in our ever more digitalised world of health care creates opportunities for better research around – and delivery of – pharmaceutical innovation. However, these opportunities may be constrained around the legal barriers to the use of health data for these purposes, which are poorly understood, particularly in relation to the new General Data Protection Regulation (GDPR).

The Office of Health Economics

Briefing
November 2018

This is OHE’s report to the Charity Commission for England and Wales for the year 2017, OHE’s first since becoming a registered charity in December 2016. It demonstrates some of the ways in which OHE has met its charitable objects: namely, to advance the education of the public in general/health care payers/policy makers on the subject of health economics and health care policy.

Pages